First-in-human Phase 1/2a clinical trial initiated for JHDD-invented glutamine antagonist for the treatment of solid tumors
JHDD coauthors a report showing glutamine antagonism overcomes tumor immune invasion [Science]
JHDD awarded a Crohn’s and Colitis Foundation grant to develop a novel treatment for IBD
JHDD received a UG3 grant through the HEAL initiative to develop new a new treatment for neuropathic pain
Partnership Awards $3 Million In Grants For Promising New Treatments In Alzheimer’s And Related Dementias
JHDD start-up Dracen Pharmaceuticals receives $40.5 million to develop Glutamine Antagonists
Our high throughput screening collaboration with Eisai and partnership with Institute of Organic Chemistry and Biochemistry represent innovative ways to create a great synergy of complimentary organizations working together to develop new therapeutics.